B-Cell Malignancies | Special Reports

October 19, 2013

In an updated analysis of the phase III MM-003 trial, Celgene International Sarl, the makers of pomalidomide, reported on a new progression-free survival (PFS) analysis and final overall survival (OS) in September 2013.

October 19, 2013

The long-term prognosis for most patients with mantle cell lymphoma (MCL) is poor, with median overall survival rates of 3 to 5 years. Because treatment is not curative, almost all patients will experience a relapse or find that their disease is refractory to treatment.

October 19, 2013

Ari M. Melnick, MD, from Weill Cornell Medical College, comments on emerging therapies for the treatment of mantle cell lymphoma.

October 19, 2013

Phase III trials in multiple myeloma, including plitidepsin, elotuzumab, carfilzomib, masitinib, and panobinostat.

October 18, 2013

A Q&A with Jennifer Brown MD, PhD, director of the Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, and assistant professor of Medicine at Harvard Medical School in Boston, MA.

October 18, 2013

Mark Weiss, MD, from the Kimmel Cancer Center at Jefferson, gives an overview of agents in development for chronic lymphocytic leukemia.

October 18, 2013

With the arrival and incorporation into clinical practice of immunomodulatory drugs and proteasome inhibitor therapy, patients with multiple myeloma patients are achieving deep, durable responses and disease control, and are living longer

October 18, 2013

Several oral drugs are in development for both non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL). “There is different activity in different lymphoma types with different oral drugs and antibodies in development,” said Andrew D. Zelenetz, MD, PhD.

October 18, 2013

Manish Sharma, MD, from the Kimmel Cancer Center at Jefferson, comments on the use of pomalidomide in relapsed/refractory multiple myeloma.

October 18, 2013

A Q&A with Andrew D. Zelenetz, MD, PhD, medical oncologist specializing in lymphoma at Memorial Sloan-Kettering Cancer Center, New York City.